Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dimethyl Fumarate in Chinese Participants with Relapsing Multiple Sclerosis
NCT05658484Phase 4Completed
- Sponsor
- Biogen
- Start
- Jun 2023
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of dimethyl fumarate in multiple sclerosis (MS), sponsored by Biogen. Primary endpoint: Annualized Relapse Rate at 48 weeks. Started Jun 2023; status: completed.
02
Drugs
dimethyl fumarate
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT05658484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05658484.